In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cliff Nearing, It's Lilly's Turn to Restructure

Executive Summary

Lilly's September reorganization will trim $1 billion in costs, but is as much about enhancing R&D productivity, the drugmaker says.
Advertisement

Related Content

AstraZeneca's Ticagrelor Brilliant At ECS Congress; Will It Outshine Effient?
Lilly Cuts Arzoxifene Losses, Will Not File NDA
Adventures in Glutamate: The Difficult and Expensive Path of Novelty in Drug Discovery
Adventures in Glutamate: The Difficult and Expensive Path of Novelty in Drug Discovery
Pfizer Restructures for a More Flexible Future
Pfizer Restructures for a More Flexible Future
Lilly and Merck Lead the Way With Asian FIPNet Strategies
Lilly and Merck Lead the Way With Asian FIPNet Strategies
Lilly's Chorus Experiment
Lilly's Chorus Experiment

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel